Skip to main content

Table 3 Changes in metabolic parameters induced by the placebo or pentoxifylline at the end of treatment

From: Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study

  Placebo (n = 70) Pentoxifylline (n = 52) P-value
BMI (kg/m2) 0.22 ± 1.75 −0.25 ± 0.80 0.079
Systolic BP (mmHg) 3.9 ± 18.3 1.3 ± 15.7 0.417
Diastolic BP (mmHg) 0.3 ± 11.8 1.8 ± 10.9 0.473
HbA1c (%) 0.09 ± 0.72 −0.34 ± 0.74 0.002
Fasting plasma glucose (mg/dL) 8.4 ± 37.4 −10.0 ± 38.9 0.009
HOMA-IRa 0.24 ± 2.61 −0.79 ± 2.03 0.041
Hs-CRP (mg/L) 0.70 ± 4.33 0.51 ± 4.32 0.818
Serum TNF-α (pg/mL) 0.14 ± 0.71 −0.24 ± 3.11 0.322
AST(U/L) 0.33 ± 13.33 −1.31 ± 7.84 0.432
ALT(U/L) −0.30 ± 14.38 −1.37 ± 8.75 0.637
r-GT(U/L) 1.19 ± 25.27 −3.90 ± 8.88 0.126
  1. Data expressed as the means ± standard deviation (SD). P-values are for comparing the absolute change in each variable between the placebo and pentoxifylline groups
  2. aHOMA-IR was measured only in subjects who were not receiving insulin treatment, placebo (n = 58), pentoxifylline (n = 39)
  3. BMI body mass index, BP blood pressure, HbA1c glycated hemoglobin, HOMA-IR homeostatic model assessment insulin resistance, hs-CRP high-sensitivity C-reactive protein, TNF tumor necrosis factor, AST aspartate aminotransferase, ALT alanine aminotransferase, r-GT, r-glutamyl transpeptidase